Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism CCNB1 inhibitors(cyclin B1 inhibitors), cyclin-A inhibitors(cyclin A2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | US | 01 Dec 2023 |